Growth expectations weigh towards H2; outlook maintained
30/04/25 -"Q1 sales slightly exceeded expectations. While the growth was largely driven by Biosimilars (similar to previous quarters), it was somewhat restrained. Nonetheless, the management retained its ..."
Pages
58
Language
English
Published on
30/04/25
You may also be interested by these reports :
30/04/25
Q1 results were ahead of expectations, driven by healthy growth in HIV, respiratory, immunology, and cancer medicines, offsetting a weaker showing ...
30/04/25
Q1 sales slightly exceeded expectations. While the growth was largely driven by Biosimilars (similar to previous quarters), it was somewhat ...
29/04/25
Q1 profits exceeded the street’s expectations, supported by a healthy performance across segments. However, the management maintained its full-year ...
29/04/25
Q1 results exceeded consensus, aided by strong performances across focus areas. Consequently, the management raised its full-year outlook. While the ...